News

Apply Now: 📣 BLUE KNIGHT ™️ Resident QuickFire Challenge: Accelerating Project NextGen

Johnson & Johnson Innovation, together with the Biomedical Advanced Research and Development Authority (BARDA), is proud to launch the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen.

Current and alumni Blue Knight residents and their collaborators are invited to submit promising potential pre-clinical or clinical solutions for the opportunity to receive award funding from a total pool of $10M to help them accelerate their potential vaccines, therapeutics, and enabling technologies.

Applicants can apply to one or both application tracks:

  • Partner: Forging collaborations can accelerate evidence generation to get to key inflection points, allowing for more rapidly deployable potential solutions that provide mutual value. For the ‘Partner’ track of this challenge, Blue Knight residents who choose to collaborate with another Blue Knight or early-stage company in their submission may apply through a joint application submission.*
  • Sole Contributor: Blue Knight residents are invited to apply to accelerate their potential solution.**

All awards are subject to the execution of the necessary (award) agreements.

*Applicants must have at least one Blue Knight resident, current or alumni, as a collaborator
**Applicants must be current or alumni Blue Knight residents

 

Learn more here.

Recent News

12/03/2024

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

12/03/2024

New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic performance, its impacts, and its geographic footprint. The report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” analyzes the sector’s economic impact via employment, overall

11/21/2024

TearSolutions, Inc. Secures $3M Series B Funding

TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface related diseases, today announced the successful closure of a $3M Series B round designed to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages. “This round of financing is significant for several reasons,